Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen R Walsh

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Open Forum Infectious Diseases|January 29, 2021
Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 VaccineesKarina Oganezova, Elvin J Fontana-Martinez, Jon A Gothing, et al.
The Journal of Infectious Diseases|November 6, 2012
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)Dan H Barouch, Jinyan Liu, Lauren Peter, et al.
Blood|May 12, 2023
Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelet donorsMichaël Desjardins, Phoebe Cunningham, Xhoi Mitre, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
The Journal of Infectious Diseases|April 11, 2014
First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. Infectious Diseases|January 10, 2026
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trialDeborah R Leitner, Stephen R Walsh, Masataka Suzuki, et al.
The Journal of Infectious Diseases|November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2021
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsSimbarashe Takuva, Shelly T Karuna, Michal Juraska, et al.
JCI Insight|June 28, 2016
Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertensionFei Liu, Christina Mallarino Haeger, Paul B Dieffenbach, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Open Forum Infectious Diseases|January 29, 2021
Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 VaccineesKarina Oganezova, Elvin J Fontana-Martinez, Jon A Gothing, et al.
The Journal of Infectious Diseases|November 6, 2012
Characterization of humoral and cellular immune responses elicited by a recombinant adenovirus serotype 26 HIV-1 Env vaccine in healthy adults (IPCAVD 001)Dan H Barouch, Jinyan Liu, Lauren Peter, et al.
Blood|May 12, 2023
Immunogenicity of quadrivalent meningococcal conjugate vaccine in frequent platelet donorsMichaël Desjardins, Phoebe Cunningham, Xhoi Mitre, et al.
The Lancet. HIV|October 3, 2020
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyLindsey R Baden, Daniel J Stieh, Michal Sarnecki, et al.
The Journal of Infectious Diseases|April 11, 2014
First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
The Lancet. Infectious Diseases|January 10, 2026
Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trialDeborah R Leitner, Stephen R Walsh, Masataka Suzuki, et al.
The Journal of Infectious Diseases|November 6, 2012
First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)Lindsey R Baden, Stephen R Walsh, Michael S Seaman, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 19, 2021
Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized TrialsSimbarashe Takuva, Shelly T Karuna, Michal Juraska, et al.
JCI Insight|June 28, 2016
Distal vessel stiffening is an early and pivotal mechanobiological regulator of vascular remodeling and pulmonary hypertensionFei Liu, Christina Mallarino Haeger, Paul B Dieffenbach, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
Pageof 8